Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Smartphone apps used as 'early warning systems' for skin cancer are poorly regulated and frequently cannot be relied upon to produce accurate results, according to new analysis by Abhilash Jain at NDORMS.

Examining patient for skin cancer © Shutterstock

Skin cancer detection apps are designed to ensure that the right people seek medical attention by providing a risk assessment of a new or changing mole. These apps use specialised algorithms to try to detect possible skin cancers.

Abhilash Jain, Assistant Professor of Plastic and Hand Surgery at NDORMS collaborated with researchers based in the University of Birmingham's Institute of Applied Health Research, and with the Centre of Evidence-Based Dermatology at the University of Nottingham to analyse a series of studies produced to evaluate the accuracy of six different apps. Their results, published in The BMJ, reveal a mixed picture, with only a small number of studies showing variable and unreliable test accuracy among the apps evaluated.

Skin cancer has one of the highest global incidences of any cancer. Early detection and treatment, particularly of melanoma, can improve survival. According to this new analysis, however, apps may cause harm from failure to identify potentially fatal skin cancers, or from over-investigation of false positive results – for example removing a harmless mole unnecessarily.

The research team was also concerned by the quality of the studies themselves, which evaluated apps using images taken by experts rather than by app users. In addition, many studies did not identify whether lesions identified as 'low risk' by the apps were in fact benign, further compromising the conclusions that can be drawn from the evaluations.

Lead researcher Dr Jac Dinnes, of the Institute of Applied Health Research at the University of Birmingham, said: "This is a fast-moving field and it's really disappointing that there is not better quality evidence available to judge the efficacy of these apps. It is vital that healthcare professionals are aware of the current limitations both in the technologies and in their evaluations."

The authors also drew attention to the regulations governing the evaluation of healthcare apps. Manufacturers can currently apply CE marks to smartphone apps without necessarily being subject to independent inspection by bodies such as the UK Medicines and Healthcare Products Regulatory Agency (MHRA). Although this may change with new Medical Device Regulations coming into force in 2020, the researchers noted that stricter assessment processes in operation in the US has resulted in no skin cancer assessment apps receiving regulatory approval.

Co-author Jon Deeks, Professor of Biostatistics in the Institute of Applied Health Research, adds: "Regulators need to become alert to the potential harm that poorly performing algorithm-based diagnostic or risk monitoring apps create. We rely on the CE mark as a sign of quality, but the current CE mark assessment processes are not fit for protecting the public against the risks that these apps present."

Abhilash Jain said: "While It is important that new technology is supported and progress made in all aspects of medicine, our study shows that in some areas of medicine the technology is not at a stage where it can replace a trained clinician. It is important that anyone who is worried about a mole sees their GP and not rely on an "app" as a substitute for professional medical advice."

The team also has made a series of recommendations for future studies of smartphone apps:

• Studies must be based on clinically-relevant population of smartphone users who may have concerns about their risk of skin cancer
• All skin lesions identified by smartphone users must be included – not just those identified as potentially problematic
• Clinical follow-up of benign lesions must be included in the study to provide more reliable and generalizable results.

Hywel Williams, Professor of Dermatology at the University of Nottingham who collaborated on the study, said: "Although I was broad minded on the potential benefit of apps for diagnosing skin cancer, I am now worried given the results of our study and the overall poor quality of studies used to test these apps. My advice to anyone worried about a possible skin cancer is 'if in doubt, check it out with your GP'."

The research was supported by the NIHR Birmingham Biomedical Research Centre and is an update of one of a collection of reviews funded by the National Institute for Health Research through its Cochrane Systematic Review Programme Grant.

Similar stories

Professor Michael Dustin appointed new Chair in Molecular Immunology

A generous gift from the Kennedy Trust for Rheumatology Research has enabled the creation of a new Chair in Molecular Immunology at the University of Oxford.

Empowering data science for single-cell analysis in Zimbabwe

An innovative computational biology training module was launched in November 2022 at the African Institute of Biomedical Science and Technology (AiBST) in Harare, Zimbabwe, where MSc students were trained in single-cell RNA sequencing data analysis.

T-cell coreceptors are well endowed—with kinases!

The kinase occupancy of CD4 and CD8 coreceptors is high, according to a new study published in PNAS.

Two prestigious Hunterian Professorships awarded to NDORMS researchers

Conrad Harrison and Tom Layton have both been awarded Hunterian Professorships for 2022 by the Royal College of Surgeons of England

Adalimumab is found to be a cost-effective treatment for early-stage Dupuytren’s disease

Researchers at the Kennedy Institute of Rheumatology and Oxford Population Health’s Health Economics Research Centre have found that anti-TNF treatment (adalimumab) is likely to be a cost-effective treatment for people affected by early-stage Dupuytren’s disease.

Patients like me

What can patients learn from the experiences of people like them who’ve already had a hip replacement? A new tool called ‘Patients like me’ helps answer some of the questions about pain, complications and how long the prosthesis might last.